




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>4</sup> :</b>  <b>A61M 25/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 89/10155</b>  <b>(43) International Publication Date:</b> 2 November 1989 (02.11.89)
<b>(21) International Application Number:</b> PCT/US89/01770 <b>(22) International Filing Date:</b> 27 April 1989 (27.04.89)  <b>(30) Priority data:</b> 187,230                      28 April 1988 (28.04.88)                      US  <b>(71) Applicant:</b> RESEARCH MEDICAL, INC. [US/US]; 1847 West 2300 South, Salt Lake City, UT 84119 (US).  <b>(72) Inventors:</b> BUCKBERG, Gerald, D. ; 13238 Riviera Range Road, Los Angeles, CA 90049 (US). TODD, Robert, J. ; 3420 South 3610 East, Salt Lake City, UT 84109 (US).  <b>(74) Agents:</b> NYDEGGER, Rick, D. et al.; Workman, Nydegger & Jensen, 1000 Eagle Gate Tower, 60 East South Temple, Salt Lake City, UT 84111 (US).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** RETROGRADE VENOUS CARDIOPLEGIA CATHETERS AND METHODS OF USE AND MANUFACTURE

**(57) Abstract**

This invention relates to a retrograde cardioplegia catheter (10) and its method of use. The catheter contains two lumens, an infusion lumen (18) through which the cardioplegic solution flows and a pressure sensing lumen (20) for monitoring the fluid pressure at the point where the solution exits the catheter. A slightly tapered, self-filling balloon (22) is secured to the distal end of the catheter (10). Also, located at the distal end of the catheter is a soft, rounded tip (14) to prevent damage to the sensitive intimal tissues of the coronary sinus (50). A stylet (36) having a handle (38) at one end and a predetermined curve at the other end enables the cardioplegia catheter (10) to be inserted quickly and accurately within the coronary sinus (50) through a very small incision made in the right atrium. After the catheter is secured in place, the stylet is withdrawn.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria  
AU Australia  
BB Barbados  
BE Belgium  
BG Bulgaria  
BJ Benin  
BR Brazil  
CF Central African Republic  
CG Congo  
CH Switzerland  
CM Cameroon  
DE Germany, Federal Republic of  
DK Denmark  
FI Finland

FR France  
GA Gabon  
GB United Kingdom  
HU Hungary  
IT Italy  
JP Japan  
KP Democratic People's Republic  
of Korea  
KR Republic of Korea  
LI Liechtenstein  
LK Sri Lanka  
LU Luxembourg  
MC Monaco  
MG Madagascar

ML Mali  
MR Mauritania  
MW Malawi  
NL Netherlands  
NO Norway  
RO Romania  
SD Sudan  
SE Sweden  
SN Senegal  
SU Soviet Union  
TD Chad  
TG Togo  
US United States of America

1

1

RETROGRADE VENOUS CARDIOPLEGIA  
CATHETERS AND METHODS OF USE  
AND MANUFACTURE

5

BACKGROUND

1. The Field of the Invention

The present invention is directed to retrograde cardioplegia catheters and the methods of their use and manufacture. More particularly, the catheters of the present invention are designed for rapid and accurate insertion into the coronary sinus and for retrograde administration of cardioplegia with maximum effectiveness and minimum tissue damage.

15

2. The Prior Art

Since the early days of cardiac surgery, it has been recognized that in order to provide the optimum surgical conditions when operating on the heart, it is necessary to interrupt the normal operation of the heart. For obvious reasons, an arrested, flaccid heart is preferred during a cardiac surgical procedure over a beating heart with blood flowing through it. Thus, in order to be able to efficiently perform cardiac surgery, it is often necessary to use cardiopulmonary-bypass techniques and to isolate the heart from its life-giving blood supply.

25

It has been found that many deaths occurring after cardiac surgery are due to acute cardiac failure. At first, it was believed that the heart was simply beyond repair and that the operation had failed to correct the problem. Later, it was discovered that many of these postoperative deaths were due to new, and often extensive,

30

35

SUBSTITUTE SHEET

-2-

1 perioperative (during or within 24 hours after the surgical  
procedure) myocardial necrosis (death of the heart tissue).  
Furthermore, many patients who survived were found to have  
suffered myocardial necrosis to a significant degree,  
5 thereby resulting in low cardiac blood output.

It is now known that myocardial necrosis occurs  
because the energy supply or reserve of the cardiac muscle  
cells is inadequate to supply the needs of the heart. The  
availability of oxygen dramatically affects the cell's  
10 ability to satisfy these energy requirements. For  
example, anaerobic metabolism of glucose produces two (2)  
moles of adenosine triphosphate ("ATP") per mole of glucose  
(as well as harmful acid metabolites), whereas aerobic  
metabolism of glucose produces thirty-six (36) moles of ATP  
15 per mole of glucose. Therefore, one of the primary goals  
of myocardial preservation techniques during surgery is to  
reduce myocardial oxygen consumption.

Myocardial oxygen consumption is significantly reduced  
by stopping the electromechanical work of the heart. The  
oxygen demands of the beating empty heart at 37°C are four  
20 to five times those of the arrested heart (*i.e.*, 4-5  
ml/100-gm/min compared with 1 ml/100-gm/min). Buckberg,  
G.D., "Strategies and Logic of Cardioplegic Delivery to  
Prevent, Avoid, and Reverse Ischemic and Reperfusion  
Damage," 93 The Journal of Thoracic and Cardiovascular  
25 Surgery, 127, 136 (January 1987) (hereinafter referred to  
as: Buckberg, "Strategies and Logic of Cardioplegic  
Delivery").

Oxygen consumption can be reduced further by cooling  
the heart. For example, the oxygen requirements of the  
30 arrested heart at 20°C are 0.3 ml/100-gm/min and are  
reduced to only 0.15 ml/100-gm/min at 10°C. On the other  
hand, the oxygen requirements of the beating or  
fibrillating heart at comparable temperatures, are 2-3

35

SUBSTITUTE SHEET

-3-

1 ml/100-gm/min. Buckberg, "Strategies and Logic of  
Cardioplegic Delivery" at 129.

5 The normal heart receives its blood supply through the  
left and right coronary arteries which branch directly from  
the aorta. Generally, the veins draining the heart flow  
into the coronary sinus which empties directly into the  
right atrium. A few veins, known as thebesian veins, open  
directly into the atria or ventricles of the heart.

10 One of the early methods utilized to protect the  
myocardium during surgery was normothermic perfusion of the  
empty beating heart. This method was utilized in an effort  
to maintain the heart, as near as possible, in normal  
conditions during surgery. Although the procedure  
eliminated the problem of blood flow, dissection and  
suturing were still difficult to perform because of the  
15 firmness of the myocardium and the beating of the heart.  
Additionally, it was found that a significant amount of  
damage still occurred to the myocardium when this procedure  
was utilized.

20 A second method which was developed to protect the  
myocardium was intermittent cardiac ischemia with moderate  
cardiac hypothermia. This method requires that the entire  
body be perfused at a temperature of from 28°C to 32°C,  
thus slowing all bodily functions, including those of the  
heart. The heart is fibrillated before aortic cross-  
25 clamping to stop the beating. The surgeon can then operate  
for approximately fifteen to twenty-five (15-25) minutes,  
after which time the heart beat is necessarily resumed for  
three to five (3-5) minutes. This procedure proved to be  
an inefficient method for performing operations and had  
30 many attendant dangers, including the fibrillation of the  
heart.

A third method which has been utilized is profound  
hypothermic cardiac ischemia. This method requires that

35

**SUBSTITUTE SHEET**

-4-

1 the temperature of the heart be lowered to about 22°C by  
the infusion of a cooled perfusate and/or by filling the  
pericardium with cold saline solution. One of the major  
disadvantages of this technique is that the heart continues  
5 to fibrillate, exhausting the heart's stored energy. As a  
result, the heart becomes acidotic, which over time causes  
irreversible muscle damage.

A fourth method which has been developed to preserve  
the myocardium during surgery is the infusion of a cold  
10 cardioplegic fluid to cool and stop the beating of the  
heart. After the initial infusion, the heart is reperfused  
approximately every thirty (30) minutes to maintain the  
cool, dormant state of the heart.

The use of cardioplegia to protect the myocardium has  
proven the most advantageous method of those used to date.  
15 Cardioplegia, which literally means "heart stop," may be  
administered in an antegrade manner (through arteries in  
the normal direction of blood flow), in a retrograde manner  
(through veins opposite the normal blood flow direction),  
or in a combination of retrograde and antegrade adminis-  
20 tration. Cardioplegic solutions, typically containing  
potassium, magnesium procaine, or a hypocalcemic solution,  
stop the heart by depolarizing cell membranes.

Cardioplegia may be induced immediately after extra-  
corporeal circulation has begun, provided that the  
25 pulmonary artery is collapsed to attest to the adequacy of  
venous return. In normal antegrade cardioplegia, a single  
venous return catheter is inserted in the right atrium to  
transfer the blood from the body to the heart-lung machine  
which pumps the blood into the aorta above an aortic clamp.  
30 Then, a single needle is inserted into the aorta beneath  
the clamp through which the cardioplegic solution is  
administered. The cardioplegic solution flows through the  
coronary arteries in the normal blood flow direction.

35

**SUBSTITUTE SHEET**

-5-

1 If aortic insufficiency exists (imperfect closure of  
the aortic valve) or the patient is undergoing aortic valve  
replacement, then direct cannulation of the coronary  
arteries is necessary to perform antegrade cardioplegia.  
5 In this technique the aortic root is opened (using the  
procedure called "aortotomy") and perfusion catheters are  
inserted into both the left and right coronary ostia.

Care must be taken to avoid mechanical injury to the  
coronary ostia which could produce the serious  
10 complications of coronary ostial stenosis (i.e.  
constricting of the coronary ostia). Ostial stenosis  
requires reparative surgery and can be quite hazardous due  
to obstruction of the coronary arteries. Moreover, it is  
a nuisance to have perfusion catheters present within the  
limited operative field during aortic valve replacement.  
15 The inconvenience and time consumed by positioning  
perfusion catheters have led to dissatisfaction with direct  
coronary perfusion.

The foregoing risks and inconvenience of direct  
coronary cannulation may be avoided by using the retrograde  
20 cardioplegia technique. For this reason, some surgeons  
select retrograde cardioplegia as the preferred method of  
myocardial protection during aortic valve replacement.

Retrograde cardioplegia is conventionally administered  
by inserting a balloon catheter within the coronary sinus,  
25 inflating the balloon to stop the normal fluid flow into  
the right atrium, and perfusing the cardioplegic solution  
backwards through the coronary veins. In order to insert  
the catheter into the coronary sinus, the right heart must  
be isolated. To isolate the right heart, both the superior  
30 and inferior venae cavae must be tied and each must be  
cannulated. Once the right heart is isolated, the right  
atrium may be opened without allowing air to enter the  
circulatory system, thereby reducing the risk of systemic

35

**SUBSTITUTE SHEET**

-6-

1 air embolization.

2 With the right atrium open, the catheter is visually  
3 inserted into the coronary sinus and hand-held while the  
4 cardioplegic solution is administered. The right atrium is  
5 then closed. This process must be repeated each time  
6 cardioplegic solution is administered during the operation.  
7 See Buckberg, "Strategies and Logic of Cardioplegic  
8 Delivery" at 132-33.

9 Retrograde cardioplegia is more complicated than  
10 antegrade cardioplegia because it requires right heart  
11 isolation, right atriotomy (i.e. opening the right atrium),  
12 and hand-holding the catheter during perfusion.  
13 Furthermore, retrograde cardioplegia may result in  
14 undesirable consequences.

15 For example, the atriotomy may lead to heart  
16 arrhythmia, and repeated cannulation may substantially  
17 injure the coronary sinus. In addition, high perfusion  
18 pressure or the failure to periodically allow normal venous  
19 drainage may damage the coronary veins and microcirculatory  
20 system causing edema. For these reasons, some surgeons  
21 completely avoid retrograde cardioplegia.

22 Nevertheless, there are some situations where  
23 retrograde cardioplegia is advisable over antegrade. For  
24 example, antegrade cardioplegia produces nonhomogeneous  
25 cooling and cardioplegic maldistribution in cases of  
26 myocardial ischemia and diffuse coronary disease.  
27 Antegrade cardioplegia does not adequately protect those  
28 areas of the heart downstream from coronary artery  
29 obstructions.

30 Several surgical graft techniques have been developed  
31 to circumvent coronary artery obstructions. In almost all  
32 of these techniques, cardioplegic solution is delivered  
33 down the grafts after they are completed. The graft is  
34 first attached to the coronary artery below the blockage,  
35

SUBSTITUTE SHEET



-7-

1 thereby leaving the other end of the graft open through  
which the cardioplegic solution can be administered. The  
open end of the graft is then attached to the aorta.  
Unfortunately, the area of the heart downstream of the  
5 obstruction does not receive any cardioplegic protection  
until after the graft is attached.

In the case of diffuse coronary artery disease, not  
all of the coronary blockages receive grafts. Therefore,  
the areas that are not grafted receive very minimal  
protection. In these situations, only retrograde  
10 cardioplegia can adequately protect those areas of the  
heart downstream from the coronary blockages.

Recently, some surgeons have begun using the internal  
mammary artery as the preferred graft for use on patients  
with coronary artery disease. It has been found that the  
15 internal mammary artery provides a superior long-term graft  
over the customary vein grafts (e.g., saphenous vein  
grafts). However, because the internal mammary artery  
remains proximally intact and insertion of a needle into  
the mammary artery would severely damage the artery,  
20 antegrade cardioplegia cannot be delivered through the  
internal mammary artery.

Many surgeons choose not to use internal mammary  
grafts in patients who have more severe forms of heart  
disease because antegrade cardioplegia is not available to  
25 protect the heart, notwithstanding the graft's superiority.  
Because antegrade cardioplegia does not adequately protect  
the heart downstream of the graft, that part of the heart  
muscle may be permanently damaged, resulting in a mortality  
or a very complicated, prolonged convalescence.

30 Although retrograde cardioplegia would provide  
adequate protection for those patients undergoing an  
internal mammary graft, surgeons often opt to use antegrade  
cardioplegia in combination with the inferior saphenous

35

**SUBSTITUTE SHEET**

-8-

1 vein graft in order to avoid the cumbersome retrograde  
cardioplegia technique. The net result is that the sick  
patient receives a good short-term benefit by surviving the  
operation. But many years later, the patient has an  
5 inferior graft which may require additional surgery.

Furthermore, it has been found that by combining  
retrograde and antegrade cardioplegia many of the  
limitations inherent in the two protection strategies may  
be overcome so that a more uniform degree of myocardial  
10 hypothermia and complete regional and global left and right  
ventricular functional recovery is possible. Nevertheless,  
clinical adoption of retrograde cardioplegic techniques,  
alone or in combination with antegrade techniques, has been  
slow despite evidence of its usefulness. The principle  
15 reason for this delay in clinical acceptance seems to stem  
from the more cumbersome operative technique that is  
required to employ retrograde cardioplegia.

Most cardiac operations in adult patients are  
performed with single venous cannulation. Thus, the need  
20 for double cannulation of the venae cavae and isolation of  
these vessels, right atriotomy, and hand-holding of the  
catheter in the coronary sinus are all additional surgical  
procedures required in order to perform retrograde  
cardioplegia. These additional procedures, combined with  
25 possible isolation of the pulmonary artery, slower time to  
arrest, and possible large volumes of the cardioplegic  
solution needed to fill the right heart have limited the  
acceptance of current retrograde techniques.

In summary, retrograde cardioplegia often can provide  
superior myocardial protection over antegrade cardioplegia  
30 alone and the combination of retrograde cardioplegia and  
antegrade cardioplegia can provide superior myocardial  
protection than either technique alone. Yet there is  
substantial resistance by many surgeons to take advantage

35

SUBSTITUTE SHEET

-9-

1 of the benefits of retrograde cardioplegia because it  
complicates an already complex surgical procedure.

From the foregoing, it will be appreciated that what  
is needed in the art are apparatus and methods for  
performing retrograde cardioplegia which are simple and  
5 effective so that the advantages of retrograde cardioplegia  
can be readily utilized by surgeons.

Additionally, it would be a significant advantage over  
the art to provide apparatus and methods for performing  
retrograde cardioplegia which do not require right atrial  
10 isolation, right atriotomy, and repeated cannulation of the  
catheter.

It would be another advancement in the art to provide  
a retrograde cardioplegia catheter which can be quickly and  
accurately inserted within the coronary sinus with  
15 relatively little trauma to the patient.

It would be yet another advancement in the art to  
provide apparatus and methods for performing retrograde  
cardioplegia which allow surgeons to safely use the  
internal mammary graft without making the surgical  
20 procedure cumbersome.

The foregoing, and other features and objects of the  
present invention, are realized in the retrograde  
cardioplegia catheter apparatus and method which are  
disclosed and claimed herein.

25

#### BRIEF SUMMARY AND OBJECTS OF THE INVENTION

The present invention is directed to retrograde  
cardioplegia catheters and their methods of use and  
30 manufacture. The catheters of the present invention  
include two lumens --- a large lumen through which the  
cardioplegic solution flows and a smaller lumen which may  
be connected to a pressure sensing device for monitoring

35

-10-

1 the fluid pressure at the point where the cardioplegic solution exits the catheter into the coronary sinus.

5 A self-filling balloon is secured near the distal end of the catheter. In the preferred embodiment of the present invention, the self-filling balloon is slightly tapered. A plurality of apertures in the larger lumen open into the self-filling balloon. These apertures allow the cardioplegic solution to fill the balloon while the fluid is flowing, but when the fluid stops, the balloon empties.

10 A low-trauma tip occludes the distal end of the catheter. The tip is rounded and soft to prevent damage to the sensitive intimal tissues of the coronary sinus. The larger lumen includes plurality of small openings located between the low-trauma tip and the self-filling balloon  
15 which allow the cardioplegic solution to exit the catheter.

A removable stylet, or "introducer," is located within the large lumen. The stylet has a predetermined curve at the distal end thereof and a handle at the proximal end which permit rapid and accurate positioning of the catheter  
20 within the coronary sinus. The stylet enables the catheter to be inserted within the coronary sinus through a very small incision made in the right atrium, as opposed to a relatively large incision (about three (3) centimeters long) necessary when the current retrograde cardioplegic  
25 technique is used. The predetermined curve at the proximal end of the stylet permits rapid and accurate positioning of the catheter within the coronary sinus. The catheter is then simply secured in place with a purse string suture, and the stylet is withdrawn from the  
30 catheter. Once securely positioned, the catheter remains in place for the duration of the operation. It will be appreciated, that the method of using the present invention avoids right atrial isolation, right atriotomy, repeated

35

SUBSTITUTE SHEET

-11-

1 cannulation of the catheter, and hand-holding of the  
catheter during retrograde perfusion of the cardioplegic  
solution.

5 As the cardioplegic solution flows through the large  
lumen of the catheter of the present invention, the self-  
filling balloon fills to seal the coronary sinus and to  
prevent the solution from flowing into the right atrium.  
The small lumen is operatively connected to a pressure  
sensing device which monitors the pressure within the  
coronary sinus. If the pressure becomes too great, the  
10 flow of cardioplegic solution is automatically stopped,  
allowing the balloon to empty and the solution to drain  
into the right atrium.

It is, therefore, an object of the present invention  
to provide apparatus and methods for performing retrograde  
15 cardioplegia which are simple and effective so that the  
advantages of retrograde cardioplegia can be readily  
utilized by surgeons.

Another important object of the present invention is  
to provide apparatus and methods for performing retrograde  
20 cardioplegia which do not require right atrial isolation,  
right atriectomy, and repeated cannulation of the apparatus.

An additional object of the present invention is to  
provide a retrograde cardioplegia catheter which may be  
25 quickly and accurately positioned within the coronary  
sinus.

Still another object of the present invention is to  
provide apparatus and methods for performing retrograde  
30

35

-12-

1 cardioplegia which allow surgeons to safely use the life-saving internal mammary graft without making the surgical procedure cumbersome.

5 These and other objects and features of the present invention will become more fully apparent from the following description and appended claims taken in conjunction with the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10 Figure 1 is a perspective view of one presently preferred embodiment within the scope of the present invention.

15 Figure 2 is a cross-sectional view of the distal end of the embodiment illustrated in Figure 1 taken along line 2-2 of Figure 1.

20 Figure 3 is a perspective view illustrating a preferred embodiment of the retrograde cardioplegic catheter of the present invention, when inserted within the coronary sinus of the heart.

Figure 4 is a partial cross-sectional perspective view of the retrograde cardioplegic catheter within the coronary sinus taken along line 4-4 of Figure 3.

25 Figure 5 is a perspective view illustrating a preferred embodiment of the present invention when used in combination with antegrade cardioplegia.

Figure 6 is a cross-sectional view of a mandrel used in manufacturing a self-filling balloon within the scope of the present invention.

30 Figure 7 is a cross-sectional view of the mandrel shown in Figure 6 in which the balloon is beginning to separate from the mandrel due to the injection of a releasing fluid.

35

-13-

1        Figure 8 is a plan view of a balloon removed from the  
mandrel and prepared for attachment to the flexible  
cannula.

5        DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A.    The Retrograde Cardioplegia Catheters

Reference is now made to the drawings wherein like  
parts are designated with like numerals throughout.  
Referring first to Figures 1 and 2, one presently preferred  
10        embodiment of an apparatus within the scope of the present  
invention is illustrated and generally designated 10.

Catheter 10 is particularly designed for the  
retrograde venous administration of cardioplegic solutions.  
The apparatus includes a flexible cannula 12 having a soft,  
15        rounded tip 14 at the distal end and a coupling device 16  
at the proximal end for attaching the catheter to a  
cardioplegic solution source. The cardioplegic solution  
would typically be provided through either a volumetric  
pump or a bag of solution within a pressure cuff.

20        Flexible cannula 12 contains two lumens: an infusion  
lumen 18 for introducing the cardioplegic solution into the  
coronary sinus and a pressure-sensing lumen 20 for  
monitoring the fluid pressure within the coronary sinus.

25        The flexible cannula is preferably constructed of a  
material which retains its flexibility after prolonged  
exposure to temperatures of at least about 0°C. In one  
current preferred embodiment, flexible cannula 12 is  
constructed of medical-grade polyvinyl chloride, having a  
30        softness of about 75 to 85 durometer, Shore-A. Other  
suitable materials, may also be used to construct flexible  
cannula 12, such as medical-grade silicone and  
polyurethane.

35

**SUBSTITUTE SHEET**

-14-

1 It is important that the flexible cannula be flexible  
enough to manipulate and position within the coronary  
sinus, but also have sufficient rigidity and structural  
5 integrity to not collapse or bend to cut off flow of the  
cardioplegic solution during use. In addition, the  
flexible cannula should be soft enough to compress or  
deflect when pressed against the coronary sinus, thereby  
protecting the coronary sinus from inadvertent puncture.  
Yet the flexible cannula should not be so soft that a tie  
10 holding it in place occludes the cannula.

As best illustrated in Figure 2, soft, rounded tip 14  
occludes the end of both infusion lumen 18 and pressure-  
sensing lumen 20. The soft rounded tip is preferably  
constructed of a material which will minimize the trauma  
and the risk of intimal damage to the coronary sinus and  
15 other heart tissues during insertion and use.

In one presently preferred embodiment of the present  
invention, the rounded tip is constructed of medical-grade  
polyvinyl chloride, having a softness of about 55 to 60  
durometer, Shore A. Other suitable materials may be used  
20 to construct the rounded tip such as silicone and  
polyurethane.

In one presently preferred embodiment, the rounded tip  
is constructed with two small appendages formed to fit  
within the infusion and pressure-sensing lumens. The fit  
25 between the rounded tip and the outer wall of flexible  
cannula 12 should be smooth to reduce the possibility of an  
exposed uneven edge injuring sensitive heart tissues.

The rounded tip is preferably solvent bonded to the  
distal end of the flexible cannula. It is important that  
30 the solvent maintains a seal or bond between the rounded  
tip and the end of the lumens during use. Additionally,  
the solvent should not create a hard surface which could  
cause trauma during insertion, use, or removal.

35

SUBSTITUTE SHEET



-15-

1 Cyclohexanone is the presently preferred solvent, but other  
solvents such as butanone (methyl ethyl ketone),  
tetrahydrofuran ("THF"), and methylene chloride are  
possible suitable substitutes.

5 A self-filling balloon 22 is located near the distal  
end of flexible cannula 12, slightly proximal from rounded  
tip 14. Self-filling balloon 22 forms an inner chamber 24  
inside the balloon and outside cannula. In one embodiment  
of the present invention, the distal end of the self-  
filling balloon is located approximately 2.0 cm to  
10 approximately 6.0 cm back from the rounded tip. Such an  
embodiment permits rounded tip 14 to be inserted far into  
the coronary sinus, yet still permit the self-filling  
balloon to seal the coronary sinus. For most purposes, the  
distal end of the self-filling balloon is preferably  
15 located about 2.0 cm to a bout 3.5 cm back from the rounded  
tip.

One preferred method of attaching the self-filling  
balloon to the flexible cannula is solvent bonding with  
tetrahydrofuran, though other solvents such as  
20 dimethylformamide ("DMF"), acetone, and cyclohexanone, for  
example, could be substituted. The balloon is attached to  
the flexible cannula according to techniques well-known in  
the art.

25 In the preferred embodiment of the present invention,  
the balloon is slightly tapered, increasing in diameter  
from the distal end to the proximal end of the balloon.  
The taper allows cardioplegic solution to be infused into  
the more distal branches of the coronary sinus, thereby  
providing thorough cardioplegic protection. A cylindri-  
30 cally shaped balloon might readily occlude the ostia of the  
more distal branches of the coronary sinus which may be as  
close as 0.5 cm from the entry of the sinus into the right  
atrium. If the ostia are occluded, then portions of the

35

**SUBSTITUTE SHEET**

-16-

1 heart upstream from the ostia would not receive  
cardioplegic protection.

2 A taper in the range of from about 25° to about 35°,  
3 measured from the longitudinal axis of the flexible cannula  
4 has been found to be suitable. Other larger or smaller  
5 tapers may be used. However, if the taper is too great,  
6 then the balloon is difficult to properly insert and  
7 position within the coronary sinus, and there is more  
8 likelihood of trauma to the tissues as the cannula is  
9 inserted and positioned. If the taper is too small, then  
10 the balloon becomes too long to fit within the coronary  
11 sinus and still engage the walls.

12 In addition, it has been found that a balloon taper  
13 within the range of the present invention performs a unique  
14 self-centering function which facilitates quick and  
15 accurate placement of the catheter within the coronary  
16 sinus.

17 A plurality of balloon apertures 26 in infusion lumen  
18 allow the flowing cardioplegic solution to inflate the  
19 balloon. The balloons of most balloon catheters known in  
20 the art expand and collapse depending upon the fluid  
21 pressure within the balloon compared with the fluid  
22 pressure outside the balloon. It has been found that the  
23 pressure required to inflate conventional balloon catheters  
24 to seal the coronary sinus often results in an excessive  
25 infusion pressure. In addition, the low operating fluid  
26 pressures used in connection with the present invention  
27 could not adequately inflate conventional balloon  
28 catheters.

29 In response to this problem, the self-filling balloon  
30 of the present invention is constructed so that it is not  
31 necessary for the balloon to expand significantly from its  
32 unfilled state in order to seal the coronary sinus. Thus,  
33 upon filling, the balloon becomes turgid but not  
34

35

SUBSTITUTE SHEET

-17-

1 significantly distended beyond the balloon's original shape.

5 The self-filling balloon preferably has a cross-sectional diameter which is slightly larger than the cross-sectional diameter of the coronary sinus. A typical adult coronary sinus has a diameter in the range of from about 1.4 cm to about 1.6 cm. Hence, in most individuals, a balloon having a cross-sectional diameter in the range of from about 1.6 cm to 2.0 cm will work.

10 In one current preferred embodiment of the present invention, the balloon has a cross-sectional diameter from about 1.7 cm to about 1.8 cm. Upon insertion within the coronary sinus, when the balloon has not been filled with cardioplegic solution, the balloon becomes slightly wrinkled about its outer periphery due to the smaller diameter of the coronary sinus. However, during infusion of the cardioplegic solution the balloon is filled and becomes turgid in order to sealingly engage the walls of the coronary sinus.

20 It will be appreciated that the coronary sinus of pediatric patients will be somewhat smaller than that of an adult patient. As a result, a retrograde cardioplegia catheter designed for pediatric use is necessarily designed so that the a self-filling balloon has a diameter to fit within the coronary sinus of the patient.

25 The total cross-sectional area of balloon apertures 26 is preferably between approximately 1.5 to approximately 5 times the cross-sectional area of infusion lumen 18 to facilitate rapid filling and emptying of the balloon. In the presently preferred embodiment within the scope of the present invention, the total cross-sectional area of apertures 26 is about 2 to 3 times the cross-sectional area of the infusion lumen.

35

SUBSTITUTE SHEET

-18-

1       The embodiment illustrated Figures 1 and 2 shows two  
balloon apertures 26. The number of openings is dependent  
on various factors. On the one hand, the total cross-  
sectional area of the apertures must be large (relative to  
5       the cross-sectional area of the infusion lumen) in order  
for the balloon to be self-filling. On the other hand, too  
many apertures or too large or improperly configured  
apertures can compromise the structural integrity of the  
catheter, thereby causing the tube to bend and/or collapse  
10       during use and inhibit flow of cardioplegic solution  
through the catheter.

Thus, there is a balance between having enough  
properly shaped and sized openings to create a large total  
cross-sectional area and having too many openings which  
weaken the catheter. In addition, the difficulty of  
15       cutting holes in the infusion lumen without damaging the  
pressure-sensing lumen must be considered in determining  
the number of balloon openings 26. Hence, while more or  
fewer apertures can be readily made to work, two have been  
found to be satisfactory for most situations.

20       A plurality of small infusion lumen outlets 28 located  
between the balloon and the rounded tip allow the  
cardioplegic solution to exit the catheter. It has been  
found that the total cross-sectional area of infusion lumen  
outlets 28 should be less than the cross-sectional diameter  
25       of the balloon openings 26. In the presently preferred  
embodiment, the total cross-sectional area of infusion  
lumen outlets 28 is in the range from about twenty-five  
percent (25%) to about seventy-five percent (75%) the  
cross-sectional area of infusion lumen 18. In the  
30       presently preferred embodiment, the total cross-sectional  
area of infusion lumen outlets 28 is approximately fifty  
percent (50%) the cross-sectional area of infusion lumen  
18.

35

SUBSTITUTE SHEET

-19-

1 In one preferred embodiment of the present invention  
there are six infusion lumen outlets, three on each side of  
infusion lumen 18 spaced about 0.2 inches apart and  
starting about 0.5 cm back from the rounded tip, each  
5 outlet having a diameter of about 0.03 inches which  
provides for a total cross-sectional area of the infusion  
lumen outlets of about fifty percent (50%) the total cross-  
sectional area of the infusion lumen. The cross-sectional  
area of the infusion lumen is in the range of from about  
10 0.007 square inches to 0.009 square inches, and preferably  
about 0.008 square inches.

The primary factor to consider in determining the  
number and size of the infusion lumen outlet is the  
resulting total cross-sectional area percentage compared to  
the cross-sectional area of the balloon aperture and/or the  
15 infusion lumen. However, care should be taken so that the  
infusion lumen outlets are not so small that the  
cardioplegic solution exits the catheter in a jet-like flow  
which could harm the coronary sinus. To further reduce any  
potential trauma to the coronary sinus from the exiting  
20 cardioplegic solution, the infusion lumen outlets are  
preferably bored in the infusion lumen at an angle so that  
the cardioplegic solution exits the catheter in a forward  
direction.

25 Because the total cross-sectional area of balloon  
aperture 26 is preferably substantially greater than the  
total cross-sectional area of infusion lumen outlets 28,  
the fluid pressure of flowing cardioplegic solution within  
the balloon inner chamber is greater than the fluid  
pressure at the point the solution exits the catheter. In  
30 this way, the self-filling balloon automatically fills as  
cardioplegic solution flows through the infusion lumen.  
When cardioplegic solution flow stops, the balloon empties  
as the solution drains into the coronary sinus.

35

-20-

1        A sensing lumen orifice 30 near the distal end of  
pressure-sensing lumen 20 permits sensing of the fluid  
pressure at the point where the cardioplegic solution exits  
the catheter within the coronary sinus. It is important to  
5        closely monitor the pressure within the coronary sinus,  
because if the fluid pressure exceeds a predetermined  
maximum pressure (as discussed in greater detail  
hereinafter), tissue damage and edema to the coronary sinus  
and other heart tissues will likely result. The cross-  
10        sectional area of sensing lumen orifice 30 is preferably  
greater than the cross-sectional area of pressure-sensing  
lumen 20. In the presently preferred embodiment, the  
cross-sectional area of sensing lumen orifice 30 is in the  
range from about 2 to about 3 times the cross-sectional  
area of pressure-sensing lumen 20.

15        A pressure-sensing feed line 32, which is an extension  
of pressure-sensing lumen 20, branches from flexible  
cannula 12 near the proximal end of the catheter. A three-  
way stopcock 34 is located at the proximal end of pressure-  
sensing feed line 32. The three-way stopcock permits  
20        coupling to a pressure-sensing device at one setting,  
removing air from the pressure-sensing lumen at a second  
setting, and sealing the feed line at the third setting.  
The pressure-sensing lumen is occluded at a point proximal  
to the point feed line 32 branches from the flexible  
25        cannula to prevent introduction of cardioplegic solution  
into the pressure-sensing lumen.

30        A removable stylet 36 is located within flexible  
cannula 12, the stylet has at the distal end a  
predetermined curve and at the proximal end a stylet handle  
38. The stylet handle contains a thumb rest 40 located at  
the proximal end thereof. A loop 42 extends outward from  
the stylet handle in the same general direction as the  
predetermined curve. The stylet is preferably constructed

35

SUBSTITUTE SHEET

-21-

1 out of a rigid material, such as a metal rod.

2 A pair of rings 44 are located just distal of the  
3 point where pressure-sensing feed line 32 branches from  
4 flexible cannula 12. Rings 44 define a suture groove 46  
5 therebetween. The suture groove enables the catheter to be  
6 tied in place after insertion within the coronary sinus.  
7 It is important to tie the catheter in position to minimize  
8 longitudinal movement of the catheter in the coronary  
9 sinus.

10 A clamp 48 is located on flexible cannula 12 between  
11 rings 44 and the point where the pressure sensing feed line  
12 branches from the flexible cannula. This clamp seals the  
13 infusion lumen and inhibits relative movement of the stylet  
14 vis-a-vis the catheter while the catheter is being inserted  
15 with the coronary sinus.

16 B. Methods of Using the Retrograde Cardioplegia Catheter

17 Referring now to Figure 3, catheter 10 is inserted  
18 into a small incision which has been made in the right  
19 atrium. The incision is preferably less than one  
20 centimeter long and is about 1 inch to about 2 inches from  
21 the entrance of the coronary sinus 50. A pulse-string  
22 suture is placed to seal the right atrium incision around  
23 the catheter.

24 Because the right atrium is not completely opened by  
25 the methods of the present invention, it is not necessary  
26 to isolate the right heart by tying and cannulating both  
27 venae cavae. This not only simplifies the surgical  
28 procedure, but also reduces the trauma experienced by the  
29 patient. In addition, because the incision in the right  
30 atrium is very small, there is little risk that the patient  
31 will develop a heart arrhythmia which often occurs when the  
32 right atrium is opened.

35

SUBSTITUTE SHEET

-22-

1       The curved stylet enables the catheter to be  
accurately positioned within the coronary sinus through  
such a small incision in the right atrium without visually  
seeing the coronary sinus. The unique stylet handle  
5       configuration gives the surgeon many options for holding  
the stylet and inserting the catheter within the coronary  
sinus. These options vary depending on the operating room  
condition, the position of the patient's heart, and the  
surgeon's own preference.

10       In one use of the present invention, the surgeon,  
standing on the patient's right side, presses the right  
index finger against loop 42, the right ring finger against  
stylet handle 38, and the thumb against thumb rest 40. In  
this position, the catheter is quickly inserted within the  
15       coronary sinus with a slight twist of the wrist by moving  
the index finger towards oneself and the thumb away from  
oneself while keeping the ring finger relatively  
stationary.

20       If the surgeon is standing on the patient's left side,  
it may be preferable to place the ring finger against the  
loop and the index finger against the stylet handle. The  
catheter can be quickly inserted by moving the ring finger  
towards oneself and the thumb away from oneself while  
keeping the index finger relatively stationary. The above  
25       grips may be reversed and modified if the surgeon prefers  
using the left hand.

30       Once in position, the catheter is secured with a  
purse-string suture around the incision in the right  
atrium. The stylet is then withdrawn, and suture groove 46  
is tied to the tourniquet tube of the purse-string suture  
as shown in Figure 3 to prevent longitudinal movement of  
the catheter in the coronary sinus. The catheter remains

35

SUBSTITUTE SHEET



-23-

1 in its proper position through the duration of the surgical  
procedure. Thus, there is no need to either repeatedly  
insert the catheter within the coronary sinus or hand-hold  
the catheter during the procedure. In this way, trauma to  
the coronary sinus is reduced and simplification of the  
5 procedure are achieved.

When the catheter is inserted within the coronary  
sinus, stylet 36 seals the infusion lumen and three-way  
stopcock 34 seals the pressure-sensing lumen. After  
insertion, the air within both the infusion and pressure  
10 sensing lumens is vented.

To accomplish this, a syringe is attached to coupling  
device 16 in order to remove any air from the infusion  
lumen. Clamp 48 is then closed until the coupling device  
is attached to a cardioplegic solution source. Similarly,  
15 the three-way stopcock is adjusted to permit removal of air  
from the pressure-sensing lumen. The three-way stopcock is  
then attached to a pressure-sensing device.

Conventional cardioplegic solutions known in the art  
may be used in performing retrograde cardioplegia within  
20 the scope of the present invention. The same cardioplegic  
solution source used for performing retrograde cardioplegia  
may be used for performing retrograde and antegrade  
cardioplegia in combination.

Generally, regardless of the type of surgical  
25 procedure involved, a venous return catheter 52 shown in  
Figure 3 would be required to enable extracorporeal  
circulation. Therefore, the method for retrograde  
administration of cardioplegic solutions disclosed herein  
does not significantly complicate the surgical procedure  
30 compared to present retrograde cardioplegia methods.

Figure 4 illustrates the proper placement of the  
catheter within coronary sinus 50. Self-filling balloon 22  
is positioned just within coronary sinus orifice 54 of  
35

-24-

1 right atrial wall 56. As the cardioplegic solution flows  
through infusion lumen 18, the fluid flows through openings  
26 to fill the self-filling balloon. Upon filling, the  
self-filling balloon is turgid but not significantly  
5 distended beyond its original shape.

During infusion of the cardioplegic solution, the  
fluid pressure within the coronary sinus is monitored. If  
the pressure rises above a predetermined maximum pressure,  
then infusion of the cardioplegic solution is stopped.  
10 Once infusion of the cardioplegic solution stops, the  
balloon empties to allow normal antegrade flow into the  
right atrium. The catheter does not need to be removed to  
allow for normal antegrade flow.

It has been found that if the pressure within the  
coronary sinus exceeds about 60 mm Hg, venular damage and  
15 hemorrhage may result. It will be appreciated that this  
maximum pressure may vary from patient to patient, but this  
pressure is a conservative maximum pressure. Therefore,  
the pressure within the coronary sinus is preferably  
maintained below approximately 50 mm Hg in order to provide  
20 a margin of error.

The pressure within the inner chamber of the self-  
filling balloon will be somewhat greater than the pressure  
within the coronary sinus due to the pressure drop  
associated with the infusion lumen outlets. Since  
25 excessive pressure within the balloon may cause the balloon  
to expand and injure the coronary sinus, the pressure  
within the balloon is preferably maintained below about 150  
mm Hg.

Because of the pressure drop through the infusion  
30 lumen and associated connectors, the pressure within the  
self-filling balloon is less than the system pressure at  
the cardioplegic solution source. If the cardioplegic  
solution contains blood, then care should be taken to

35

SUBSTITUTE SHEET

-25-

1 maintain the fluid pressure within the entire cardioplegia  
system below approximately 300 mm Hg. It has been found  
that blood subjected to pressures exceeding about 300 mm Hg  
is subject to hemolysis.

5 The cardioplegic solution flow rate should be adjusted  
to maintain a safe pressure within the coronary sinus,  
within the inner chamber of the self-filling balloon, and  
throughout the cardioplegia system. The flow rate is  
preferably maximized within the above constraints.

10 Under anticipated operating conditions, the flow rate  
of cardioplegic solution will be preferably in the range  
from about 200 ml/min to about 300 ml/min. The flow rate  
may vary depending upon the extent of coronary obstructions  
within the patient's heart and upon other heart conditions  
15 such as heart temperature and muscular tone of the coronary  
circulatory system.

Because the catheter is positioned within the coronary  
sinus during the entire surgical procedure, additional  
cardioplegic solution may be readily administered as  
needed. There is no need to repeatedly insert the catheter  
20 within the coronary sinus or to hand hold the catheter  
during infusion. Thus, the present invention facilitates  
periodic infusion and its associated benefits. Periodic  
infusion is necessary because all hearts receive some  
noncoronary collateral blood flow which tends to wash away  
25 the cardioplegic solution. Periodic infusion of  
cardioplegic solution at about twenty to thirty minute  
intervals counteracts noncoronary collateral washout.

During lengthy cardiac surgery, periodic infusion of  
the cardioplegic solution provides a number of significant  
30 benefits. For example, periodic infusion (1) maintains  
arrest, (2) restores desired levels of hypothermia, (3)  
buffers acidosis, (4) washes acid metabolites away which  
inhibit continued anaerobiosis, (5) replenishes high-energy

35

SUBSTITUTE SHEET

-26-

1 phosphates if the cardioplegia solution is oxygenated, (6)  
restores substrates depleted during ischemia, and (7)  
counteracts edema. Buckberg, "Strategies and Logic of  
Cardioplegic Delivery" at 131.

5 The present invention is particularly useful in  
delivering retrograde venous cardioplegia in combination  
with antegrade cardioplegia. A combination of retrograde  
and antegrade cardioplegia provides more homogeneous  
distribution of the cardioplegic solution to the right and  
10 left ventricles, stops the heart faster, and leads to more  
complete regional recovery of the jeopardized muscle and  
the global left and right ventricles than use of antegrade  
cardioplegia alone.

Figure 5 illustrates one method of delivering  
antegrade and retrograde cardioplegia in combination.  
15 Antegrade catheter 58 is inserted according to the  
techniques of the prior art. Retrograde catheter 10 is  
inserted within the coronary sinus as described above. The  
initial infusion is made antegrade to achieve the most  
rapid arrest of the heart tissues supplied by unobstructed  
20 coronary arteries. Aortic infusion line 60 is clamped with  
aortic clamp 62 immediately after antegrade cardioplegia  
has been administered. Vent line 64 is then opened by  
releasing a vent clamp 66. Retrograde clamp 68 is opened  
and retrograde cardioplegia is delivered via the coronary  
25 sinus to accomplish arrest and protection of regions  
supplied by constricted or occluded coronary arteries.  
Venous return catheter 52 captures the venous return of  
retrograde cardioplegic solution that flows into the right

30

35

SUBSTITUTE SHEET

-27-

1 atrium through the thebesian channels. This protocol can  
be repeated during the surgical procedure when necessary  
for periodic infusion of cardioplegic solution.

5 C. Methods of Manufacturing the Self-filling Balloon

Unlike other balloons manufactured for use with  
balloon catheters, the balloon of the present invention  
does not stretch significantly past its original shape and  
size during use. Hence, the balloon of the present  
invention is to be distinguished from the typical prior art  
10 balloon catheters which are intended to inflate to several  
times their original size. Therefore, the balloon of the  
present invention is manufactured at approximately the size  
required for proper use.

15 The balloon of the present invention is formed on a  
balloon mandrel having dimensions corresponding to the  
shape and size of the balloon. One such mandrel is  
illustrated in Figure 6. Balloon mandrel 70 includes a  
mandrel tip 72 and a mandrel shank 74. Located between the  
mandrel tip and shank is balloon mold 76. The diameter of  
20 the mandrel tip and shank is approximately the same as the  
diameter of the flexible cannula to which the balloon is to  
be ultimately securely attached.

To form a balloon, the balloon mandrel is dipped into  
a polymer solution which leaves a thin polymer coating on  
25 the mandrel surface. After the polymer has cured, the  
balloon is removed by peeling the thin coating off the  
mandrel.

The polymer should be capable of being placed in  
solution. However, the viscosity of the polymer solution  
30 affects the quality of the resulting balloon. If the  
viscosity is too high, then the balloon is too thick around  
those portions of the mandrel removed last from the  
solution. If the viscosity is too low, then the mandrel

35

SUBSTITUTE SHEET

-28-

1 must be repeatedly dipped into the polymer solution to form  
a balloon thick enough for practical use. Such a thickness  
would be in the range from about 0.003 inches to about  
0.005 inches with the presently preferred thickness being  
5 about 0.004 inches. The presently preferred viscosity of  
the polymer solution is about that of light honey.

The speed with which the mandrel is dipped into and  
removed from the polymer solution also affects the quality  
of the resulting balloon. If the mandrel is dipped too  
10 fast, then air bubbles are entrained within the polymer  
solution. If the mandrel is removed too fast, the polymer  
solution tends to drag on the mandrel surface leaving  
streaks of uneven thickness on the balloon. Dipping and  
removing the mandrel too slowly permits the polymer  
15 solution to evaporate, altering the viscosity of the  
solution. The time to dip the mandrel should be in the  
range from about 45 seconds to about 75 seconds, while the  
time to remove the mandrel should be in the range from  
about 135 seconds to about 165 seconds. The presently  
20 preferred time to dip the mandrel is about 60 seconds and  
the time to remove the mandrel is about 150 seconds.

It will be appreciated that in order to remove the  
balloon from the mandrel, the balloon portion formed around  
the mandrel shank must stretch to the balloon's maximum  
25 diameter. Thus, the polymer used to form the balloon must  
have excellent elongation properties, preferably with a  
percent elongation greater than about 600%. In addition,  
the shape of the balloon should not deform during its  
removal from the balloon mandrel.

30 Because the balloon is designed for in vivo use, it  
should preferably be constructed of a material which  
exhibits very low thrombogenicity. It has been found that  
the balloon may be suitably constructed of polyurethane.  
One preferred type of polyurethane is medical-grade

35

SUBSTITUTE SHEET

-29-

1   TECOFLEX polyurethane, manufactured by Thermedics (Woburn,  
Massachusetts), which may be purchased in a solution form.  
More detailed information regarding this product is set  
forth in United States Patent No. 4,447,590.

5       A quantity of polyurethane is preferably dissolved in  
tetrahydrofuran to form a solution having a concentration  
in the range from about 8% to about 9% polyurethane. This  
concentration results in a solution viscosity such that the  
mandrel is dipped into the solution three (3) times in  
order to achieve the desired balloon thickness.

10       Despite its apparent advantages, polyurethane  
possesses a high affinity for itself. Raw polyurethane  
tends to bind with raw polyurethane. The untreated  
surfaces of a newly formed balloon tend to bind together  
upon removal from the balloon mandrel, thereby resulting in  
15   a wrinkled, useless polyurethane mass. Therefore, in order  
to successfully construct balloons for use in the  
retrograde cardioplegia catheter of the present art with  
polyurethane, the balloon surfaces must be coated with a  
substance that will inhibit the self-affinity of  
20   polyurethane.

Several coating techniques known in the prior art have  
been considered and rejected as unsuitable. One such  
technique is to coat the mandrel with a powder, such as  
talcum powder, before dipping into the polyurethane  
25   solution. The resulting balloon contained trace amounts of  
talcum powder within the inner chamber. Because the  
balloon is self-filling, the risk of talcum powder being  
introduced into a patient's blood supply is considered  
unacceptable.

30       In another technique, the mandrel was coated with a  
thin layer of silicone prior to dipping the mandrel into  
the polyurethane solution. However, the resulting balloon  
contained an uneven layer of polyurethane. This is

35

-30-

likewise considered unacceptable.

Thus a principal problem in manufacturing the self-filling balloon within the scope of the present invention is to coat the inner surface of the balloon after the balloon had been formed, but before removal from the mandrel.

This problem is solved according to the present invention by injecting a coating agent through a borehole in the center of the mandrel such that the coating agent exits the mandrel at the juncture between mandrel tip 72 and balloon mold 76. The coating agent proceeds back along the surface of the balloon mold towards the mandrel shank until the entire inner surface of the balloon is coated.

As illustrated in Figure 6, there is a hollow bore 78 through the center of the balloon mandrel. The mandrel tip, which is threadably attached to the balloon mold, also possesses a corresponding hollow bore which opens into two exit holes 80.

Referring now to Figure 7, to release a balloon 82 formed around the periphery of the balloon mold, a coating agent 84 is injected through the hollow bore, through the exit holes, and out the juncture between the mandrel tip and balloon mold. The coating agent separates the balloon from the mandrel as it proceeds along the surface of the balloon mold.

One suitable coating agent is a solution silicone dissolved in freon having a concentration of silicone in the range from about 3% to about 10%. In one presently preferred embodiment, the silicone concentration in freon is about 5%. The freon rapidly evaporates leaving a thin film of silicone. The silicone also facilitates removal of the balloon by lubricating the mandrel. The same silicone/freon solution is preferably applied to the outer surface of the balloon to prevent self adhesion of the



-31-

1 polyurethane.

Figure 8 illustrates a balloon which has been removed from the mandrel and prepared for attachment to the cannula. In order to prepare the balloon for attachment to the cannula, the portions of the balloon formed around the  
5 mandrel tip and shank are cut leaving two sleeves 86, preferably about one eighth (1/8) inch long, extending from each end of the balloon. The sleeves are then preferably solvent bonded to the flexible cannula. As mentioned above, Tetrahydrofuran is the solvent of choice.

10 From the foregoing, it will be appreciated that the present invention provides apparatus and methods for performing retrograde cardioplegia which are simple and effective so that the advantages of retrograde cardioplegia can be readily utilized by surgeons.

15 Additionally, it will be appreciated that the present invention further provides apparatus and method for performing retrograde cardioplegia which do not require right atrial isolation, right atriotomy, and repeated cannulation of the apparatus.

20 Likewise, it will be appreciated that because the present invention provides a retrograde cardioplegia catheter which can be quickly and accurately inserted within the coronary sinus, the patient suffers relatively little trauma.

25 It will also be appreciated that the present invention provides apparatus and methods for performing retrograde cardioplegia which allow surgeons to safely use the life-saving internal mammary graft without making the surgical procedure cumbersome.

30 Finally, it will be appreciated that the present invention provides a method for manufacturing a self-filling balloon adapted for use with a retrograde cardioplegia catheter which can be safely and efficiently

35

-32-

1 coated with an agent for preventing self adhesion.

5 The present invention may be embodied in other  
specific forms without departing from its spirit or  
essential characteristics. The described embodiments are  
to be considered in all respects only as illustrative and  
not restrictive. The scope of the invention is, therefore,  
10 indicated by the appended claims rather than by the  
foregoing description. All changes which come within the  
meaning and range of equivalency of the claims are to be  
embraced within their scope.

15 What is claimed is:

20

25

30

35

-33-

1           1. A catheter for performing retrograde venous  
cardioplegia by delivering a cardioplegic solution into the  
coronary sinus of the heart, the catheter comprising:

5           a flexible cannula of a size capable of insertion  
into the coronary sinus of the heart, said cannula  
having an infusion lumen;

          a balloon attached to the cannula periphery near  
the distal end of the cannula, thereby forming a  
chamber between the balloon and the cannula;

10           at least one balloon aperture in the infusion  
lumen positioned such that the infusion lumen is in  
communication with the chamber formed by the balloon  
and the cannula through the at least one first  
opening, the aggregate of said balloon apertures  
15           having a total cross-sectional area which is greater  
than the cross-sectional area of the infusion lumen;  
and

          at least one infusion lumen outlet in the  
infusion lumen positioned between the balloon and the  
20           distal end of the cannula such that, when cardioplegic  
solution passes through the infusion lumen, a portion  
of the cardioplegic solution enters the chamber  
through the at least one balloon aperture and a  
portion of the cardioplegic solution exits the  
25           infusion lumen and the cannula through the at least  
one second opening, the aggregate of said infusion  
lumen outlets having a total cross-sectional area  
which is in the range of from about twenty-five  
percent to about seventy-five percent of the cross-  
30           sectional area of the infusion lumen, thereby creating  
a pressure within the infusion lumen which causes the  
cardioplegic solution to enter the chamber through the  
at least one first opening in order to fill the

35

-34-

1 balloon until it is turgid and in sealing engagement  
with the walls of the coronary sinus.

2. A catheter as defined in claim 1, wherein said  
5 flexible cannula is a dual lumen cannula, said cannula  
having a sensing lumen in addition to the infusion lumen,  
said catheter further comprising at least one sensing lumen  
orifice in the sensing lumen between the balloon and the  
distal end of the cannula.

10 3. A catheter as defined in claim 1, further  
comprising a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and the  
sensing lumen are occluded at the tip, the tip being  
15 configured and made of a material such that trauma to the  
coronary sinus is minimized during insertion of the  
cannula.

4. A catheter as defined in claim 2, further  
20 comprising means attached to the proximal end of the  
infusion lumen for introducing the cardioplegic solution  
into and through the infusion lumen.

5. A catheter as defined in claim 4, further  
25 comprising means attached to the proximal end of the  
sensing lumen for sensing the pressure of the cardioplegic  
solution at the at least one sensing lumen orifice.

6. A catheter as defined in claim 1, wherein the  
30 balloon is tapered from the distal end to the proximal end  
of the balloon, thereby minimizing trauma during the  
insertion of the cannula into the coronary sinus and  
thereby encouraging the sealing engagement of the balloon  
with the walls of the coronary sinus.

35

-35-

1        7. A catheter as defined in claim 6, wherein the  
balloon taper is in the range from about 25° to about 35°  
measured from the longitudinal axis of the cannula.

5        8. A catheter as defined in claim 1, wherein the  
aggregate of said balloon apertures has a total cross-  
sectional area in the range of from about 1.5 to about 5  
times the cross-sectional area of the infusion lumen.

10       9. A catheter as defined in claim 1, wherein the  
aggregate of said balloon apertures has a total cross-  
sectional area in the range from about 2 to about 3 times  
the cross-sectional area of the infusion lumen.

15       10. A catheter as defined in claim 1, wherein the  
balloon has an unfilled cross-sectional diameter greater  
than the cross-sectional diameter of the coronary sinus.

20       11. A catheter as defined in claim 1, wherein the  
balloon, when filled with cardioplegic solution, has a  
cross-sectional diameter in the range of from about 1.6 to  
about 2.0 centimeters.

25       12. A catheter as defined in claim 1, wherein the  
balloon when filled with cardioplegic solution, has a  
cross-sectional diameter in the range of from about 1.7 to  
about 1.8 centimeters.

30       13. A catheter as defined in claim 4, further  
comprising means for stopping the introduction of the  
cardioplegic solution into the infusion lumen when the  
pressure of the cardioplegic solution exiting the at least  
one infusion lumen outlet exceeds a predetermined maximum

35

SUBSTITUTE SHEET

-36-

pressure.

1

14. A catheter as defined in claim 2, wherein the tip located at the distal end of the cannula is constructed of a material having a softness in the range from about 55 to about 60 durometer, Shore-A.

5

15. A catheter as defined in claim 14, wherein the tip located at the distal end of the cannula is constructed of medical grade polyvinyl chloride.

10

16. A catheter as defined in claim 1, wherein the dual lumen cannula is constructed of a material having a softness in the range from about 75 to about 85 durometer, Shore-A.

15

17. A catheter as defined in claim 16, wherein the dual lumen cannula is constructed of medical grade polyvinyl chloride.

20

18. A catheter as defined in claim 3, wherein the distal end of the balloon is located back from the tip a distance in the range from about 2 centimeters to about 6 centimeters.

25

19. A catheter as defined in claim 1, wherein the balloon is constructed of a material having a percent elongation greater than about 600%.

30

20. A catheter as defined in claim 19, wherein the balloon is constructed of polyurethane.

35

21. A catheter as defined in claim 1, further comprising a plurality of balloon apertures in the infusion

-37-

lumen.

1

22. A catheter as defined in claim 1, further comprising a plurality of infusion lumen outlets in the infusion lumen.

5

23. A catheter as defined in claim 21, further comprising a plurality of infusion lumen outlets in the infusion lumen.

10

24. A catheter as defined in claim 21, wherein said flexible cannula is a dual lumen cannula, said cannula having a sensing lumen in addition to the infusion lumen, and wherein the balloon is tapered from the distal end to the proximal end of the balloon, thereby minimizing trauma during the insertion of the cannula into the coronary sinus and thereby encouraging the sealing engagement of the balloon with the walls of the coronary sinus, said catheter further comprising:

15

at least one sensing lumen orifice in the sensing lumen between the balloon and the distal end of the cannula; and

20

a tip located at the distal end of the cannula such that the distal ends of the infusion lumen and the sensing lumen are occluded at the tip, the tip being configured and made of a material such that trauma to the coronary sinus is minimized during insertion of the cannula.

25

25. A catheter as defined in claim 22, wherein said flexible cannula is a dual lumen cannula, said cannula having a sensing lumen in addition to the infusion lumen, and wherein the balloon is tapered from the distal end to the proximal end of the balloon, thereby minimizing trauma

30

35

-38-

1 during the insertion of the cannula into the coronary sinus  
and thereby encouraging the sealing engagement of the  
balloon with the walls of the coronary sinus, said catheter  
further comprising:

5 at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

10 a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and  
the sensing lumen are occluded at the tip, the tip  
being configured and made of a material such that  
trauma to the coronary sinus is minimized during  
insertion of the cannula.

15 26. A catheter as defined in claim 23, wherein said  
flexible cannula is a dual lumen cannula, said cannula  
having a sensing lumen in addition to the infusion lumen,  
and wherein the balloon is tapered from the distal end to  
the proximal end of the balloon, thereby minimizing trauma  
during the insertion of the cannula into the coronary sinus  
20 and thereby encouraging the sealing engagement of the  
balloon with the walls of the coronary sinus, said catheter  
further comprising:

25 at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

30 a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and  
the sensing lumen are occluded at the tip, the tip  
being configured and made of a material such that  
trauma to the coronary sinus is minimized during  
insertion of the cannula.

35



-39-

1 27. A catheter for performing retrograde venous cardioplegia by delivering a cardioplegic solution into the coronary sinus of the heart, the catheter comprising:

5 a flexible, dual lumen cannula of a size capable of insertion into the coronary sinus of the heart, said cannula having an infusion lumen and a sensing lumen;

10 a balloon attached to the cannula periphery near the distal end of the cannula, thereby forming a chamber between the balloon and the cannula;

15 at least one balloon aperture in the infusion lumen positioned such that the infusion lumen is in communication with the chamber formed by the balloon and the cannula through the at least one first opening;

20 at least one infusion lumen outlet in the infusion lumen positioned between the balloon and the distal end of the cannula such that, when cardioplegic solution passes through the infusion lumen, a portion of the cardioplegic solution enters the chamber through the at least one balloon aperture and a portion of the cardioplegic solution exits the infusion lumen and the cannula through the at least one second opening, the aggregate of said infusion lumen outlets having a total cross-sectional area which is less than the total cross-section area of the aggregate of said balloon apertures in the infusion lumen, thereby creating a pressure within the infusion lumen which causes the cardioplegic solution to enter the chamber through the at least one balloon aperture in order to fill the balloon until it is turgid and in sealing engagement with the walls of the coronary sinus;

35

SUBSTITUTE SHEET

-40-

1           at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

5           a stylet removably positioned within the flexible  
cannula, said stylet having a handle at the proximal  
end thereof and a predetermined curve at the distal  
end thereof, said stylet being constructed of a rigid  
material such that the stylet can be used to position  
the flexible cannula in the coronary sinus with  
minimal trauma to the heart tissues.

10           28. A catheter defined in claim 27, further  
comprising a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and the  
sensing lumen are occluded at the tip, the tip being  
15           configured and made of a material such that trauma to the  
coronary sinus is minimized during insertion of the  
cannula.

20           29. A catheter as defined in claim 27, further  
comprising means attached to the proximal end of the  
infusion lumen for introducing the cardioplegic solution  
into and through the infusion lumen.

25           30. A catheter as defined in claim 29, further  
comprising means attached to the proximal end of the  
sensing lumen for sensing the pressure of the cardioplegic  
solution at the at least one sensing lumen orifice.

30           31. A catheter as defined in claim 27, wherein the  
balloon is tapered from the distal end to the proximal end  
of the balloon, thereby minimizing trauma during the  
insertion of the cannula into the coronary sinus and  
thereby encouraging the sealing engagement of the balloon

35

-41-

1 with the walls of the coronary sinus.

32. A catheter as defined in claim 31, wherein the  
balloon taper is in the range from about 25° to about 35°  
measured from the longitudinal axis of the cannula.  
5

33. A catheter as defined in claim 27, wherein the  
aggregate of said balloon apertures has a total cross-  
sectional area in the range of from about 1.5 to about 5  
times the cross-sectional area of the infusion lumen.  
10

34. A catheter as defined in claim 27, wherein the  
aggregate of said balloon apertures has a total cross-  
sectional area in the range from about 2 to about 3 times  
the cross-sectional area of the infusion lumen.  
15

35. A catheter as defined in claim 27, wherein the  
balloon has an unfilled cross-sectional diameter greater  
than the cross-sectional diameter of the coronary sinus.

20 36. A catheter as defined in claim 27, wherein the  
balloon, when filled with cardioplegic solution, has a  
cross-sectional diameter in the range of from about 1.6 to  
about 2.0 centimeters.

25 37. A catheter as defined in claim 27, wherein the  
balloon when filled with cardioplegic solution, has a  
cross-sectional diameter in the range of from about 1.7 to  
about 1.8 centimeters.

30 38. A catheter as defined in claim 29, further  
comprising means for stopping the introduction of the  
cardioplegic solution into the infusion lumen when the  
pressure of the cardioplegic solution exiting the at least  
35

-42-

1 one infusion lumen outlet exceeds a predetermined maximum pressure.

5 39. A catheter as defined in claim 28, wherein the tip located at the distal end of the cannula is constructed of a material having a softness in the range from about 55 to about 60 durometer, Shore-A.

10 40. A catheter as defined in claim 39, wherein the tip located at the distal end of the cannula is constructed of medical grade polyvinyl chloride.

15 41. A catheter as defined in claim 27, wherein the dual lumen cannula is constructed of a material having a softness in the range from about 75 to about 85 durometer, Shore-A.

20 42. A catheter as defined in claim 41, wherein the dual lumen cannula is constructed of medical grade polyvinyl chloride.

25 43. A catheter as defined in claim 28, wherein the distal end of the balloon is located back from the tip a distance in the range from about 2 centimeters to about 6 centimeters.

30 44. A catheter as defined in claim 27, wherein the balloon is constructed of a material having a percent elongation greater than about 600%.

35 45. A catheter as defined in claim 44, wherein the balloon is constructed of polyurethane.

SUBSTITUTE SHEET

-43-

1       46. A catheter as defined in claim 27, further  
comprising a plurality of first openings in the infusion  
lumen.

5       47. A catheter as defined in claim 27, further  
comprising a plurality of second openings in the infusion  
lumen.

10       48. A catheter as defined in claim 46, wherein the  
distal end of the balloon is located back from the tip a  
distance in the range from about 2 centimeters to about 6  
centimeters.

15       49. A catheter as defined in claim 46, wherein said  
flexible cannula is a dual lumen cannula, said cannula  
having a sensing lumen in addition to the infusion lumen,  
and wherein the balloon is tapered from the distal end to  
the proximal end of the balloon, thereby minimizing trauma  
during the insertion of the cannula into the coronary sinus  
and thereby encouraging the sealing engagement of the  
20       balloon with the walls of the coronary sinus, said catheter  
further comprising:

at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

25       a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and  
the sensing lumen are occluded at the tip, the tip  
being configured and made of a material such that  
trauma to the coronary sinus is minimized during  
30       insertion of the cannula.

50. A catheter as defined in claim 47, wherein said  
flexible cannula is a dual lumen cannula, said cannula

35

SUBSTITUTE SHEET

-44-

1 having a sensing lumen in addition to the infusion lumen,  
and wherein the balloon is tapered from the distal end to  
the proximal end of the balloon, thereby minimizing trauma  
during the insertion of the cannula into the coronary sinus  
and thereby encouraging the sealing engagement of the  
5 balloon with the walls of the coronary sinus, said catheter  
further comprising:

at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

10 a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and  
the sensing lumen are occluded at the tip, the tip  
being configured and made of a material such that  
trauma to the coronary sinus is minimized during  
15 insertion of the cannula.

51. A catheter as defined in claim 48, wherein said  
flexible cannula is a dual lumen cannula, said cannula  
having a sensing lumen in addition to the infusion lumen,  
20 and wherein the balloon is tapered from the distal end to  
the proximal end of the balloon, thereby minimizing trauma  
during the insertion of the cannula into the coronary sinus  
and thereby encouraging the sealing engagement of the  
balloon with the walls of the coronary sinus, said catheter  
25 further comprising:

at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

30 a tip located at the distal end of the cannula  
such that the distal ends of the infusion lumen and  
the sensing lumen are occluded at the tip, the tip  
being configured and made of a material such that  
trauma to the coronary sinus is minimized during

35

SUBSTITUTE SHEET

-45-

insertion of the cannula.

1

52. A catheter for performing retrograde venous cardioplegia by delivering a cardioplegic solution into the coronary sinus of the heart, the catheter comprising:

5

a flexible, dual lumen cannula of a size capable of insertion into the coronary sinus of the heart, said cannula having an infusion lumen and a sensing lumen;

10

a tip located at the distal end of the cannula such that the distal ends of the infusion lumen and the sensing lumen are occluded at the tip, the tip being configured and made of a material such that trauma to the coronary sinus is minimized during insertion of the cannula;

15

a balloon attached about and to the cannula periphery near the distal end of the cannula, thereby forming a chamber between the balloon and the cannula, said balloon being tapered from the distal end to the proximal end of the balloon, thereby minimizing trauma during the insertion of the cannula into the coronary sinus and thereby encouraging sealing engagement of the balloon with the walls of the coronary sinus;

20

a plurality of balloon apertures in the infusion lumen positioned such that the infusion lumen is in communication with the chamber formed by the balloon and the cannula through the balloon apertures, the aggregate of said balloon apertures having a total cross-sectional area in the range from about 1.5 to about 5 times the cross-sectional area of the infusion lumen;

25

30

a plurality of infusion lumen outlets in the infusion lumen positioned between the balloon and the distal end of the cannula such that, when cardioplegic

35

-46-

1 solution passes through the infusion lumen, a portion  
of the cardioplegic solution enters the chamber  
through the balloon apertures and a portion of the  
cardioplegic solution exits the infusion lumen and the  
5 cannula through the infusion lumen outlets, the  
aggregate of said infusion lumen outlets having a  
total cross-sectional area which is in the range from  
about twenty-five to about seventy-five percent cross-  
section area of the infusion lumen, thereby creating  
10 a pressure within the infusion lumen which causes the  
cardioplegic solution to enter the inner chamber  
through the balloon apertures in order to fill the  
balloon until it is turgid and in sealing engagement  
with the walls of the coronary sinus;

15 at least one sensing lumen orifice in the sensing  
lumen between the balloon and the distal end of the  
cannula; and

20 a stylet removably positioned within the flexible  
cannula, said stylet having a handle at the proximal  
end thereof and a predetermined curve at the distal  
end thereof, said stylet being constructed of a rigid  
material such that the stylet can be used to position  
the flexible cannula in the coronary sinus with  
minimal trauma to the heart tissues.

25 53. A catheter as defined in claim 52, wherein the  
aggregate of said balloon apertures has a total cross-  
sectional area in the range from about 2 to about 3 times  
the cross-sectional area of the infusion lumen.

30 54. A catheter as defined in claim 52, wherein the  
balloon has an unfilled cross-sectional diameter greater  
than the cross-sectional diameter of the coronary sinus.

35

SUBSTITUTE SHEET



-47-

55. A catheter as defined in claim 52, wherein the balloon, when filled with cardioplegic solution, has a cross-sectional diameter in the range of from about 1.6 to about 2.0 centimeters.

56. A catheter as defined in claim 52, wherein the balloon when filled with cardioplegic solution, has a cross-sectional diameter in the range of from about 1.7 to about 1.8 centimeters.

57. A catheter as defined in claim 55, wherein the distal end of the balloon is located back from the tip a distance in the range from about 2 centimeters to about 6 centimeters.

58. A catheter as defined in claim 57, wherein the balloon is constructed of a material having a percent elongation greater than about 600%.

59. A catheter as defined in claim 58, wherein the balloon is constructed of polyurethane.

60. A catheter as defined in claim 57, wherein the balloon taper is in the range from about 25° to about 35° measured from the longitudinal axis of the cannula.

61. A catheter as defined in claim 57, further comprising means attached to the proximal end of the infusion lumen for introducing the cardioplegic solution into and through the infusion lumen.

62. A catheter as defined in claim 61, further comprising means attached to the proximal end of the sensing lumen for sensing the pressure of the cardioplegic

-48-

solution at the sensing lumen orifice.

63. A catheter as defined in claim 62, further comprising means for stopping the introduction of the cardioplegic solution into the infusion lumen when the pressure of the cardioplegic solution exiting the sensing lumen orifice exceeds a predetermined maximum pressure.

64. A catheter as defined in claim 57, wherein the tip located at the distal end of the cannula is constructed of a material having a softness in the range from about 55 to about 60 durometer, Shore-A.

65. A catheter as defined in claim 64, wherein the tip located at the distal end of the cannula is constructed of medical grade polyvinyl chloride.

66. A catheter as defined in claim 64, wherein the dual lumen cannula is constructed of a material having a softness in the range from about 75 to about 85 durometer, Shore-A.

67. A catheter as defined in claim 66, wherein the dual lumen cannula is constructed of medical grade polyvinyl chloride.

68. A method for the retrograde administration of a cardioplegic solution into the coronary sinus of the heart, the method comprising the steps of:

inserting a catheter through a small incision in the right atrium, said catheter comprising:

a cannula having an outlet near its distal end such that cardioplegic solution can be introduced into and passed through the cannula

SUBSTITUTE SHEET

-49-

and exit the outlet;

a self-filling balloon secured about the cannula at a point proximal of the outlet of the cannula such that as cardioplegic solution passes through the cannula, a portion of the cardioplegic solution fills the balloon and a portion exits the cannula through the outlet; and

a removable curved stylet located within the cannula;

manipulating the stylet to position the catheter within the coronary sinus such that the balloon, when filled with cardioplegic solution, will be in engagement with the walls of the coronary sinus;

securing the catheter in place in order to minimize longitudinal movement of the balloon and outlet of cannula within the coronary sinus;

withdrawing the stylet from within the catheter;  
and

injecting cardioplegic solution through the cannula at sufficient pressure such that the balloon fills to sealingly engage the walls of the coronary sinus, thereby permitting retrograde administration of the cardioplegic solution.

69. A method for the retrograde administration of cardioplegic solution as defined in claim 68, further comprising the step of monitoring the pressure of the cardioplegic solution within the coronary sinus in order to minimize damage to the coronary sinus by excessive pressures and flow rates of the cardioplegic solution.

70. A method for the retrograde administration of cardioplegic solution as defined in claim 68, further comprising terminating the injection of the cardioplegic

-50-

solution through the catheter such that the self-filling balloon empties to permit normal venous fluid flow into the right atrium.

71. A method for the retrograde administration of a cardioplegic solution as defined in claim 69, further comprising the step of terminating the injection of the cardioplegic solution through the cannula if the fluid pressure within the coronary sinus exceeds a predetermined maximum pressure.

72. A method for the retrograde administration of a cardioplegic solution as defined in claim 68, further comprising the step of maintaining the fluid pressure within the coronary sinus below about 50 mmHg.

73. A method for the retrograde administration of a cardioplegic solution as defined in claim 68, wherein the cardioplegic solution is injected through the cannula at a flow rate in the range from about 200 ml/min to about 300 ml/min.

74. A method for the retrograde administration of a cardioplegic solution as defined in claim 70, further comprising the step of periodically injecting cardioplegic solution through the cannula and terminating the injection of the cardioplegic solution.

75. A method for the retrograde administration of a cardioplegic solution as defined in claim 70, wherein after terminating the injection of the cardioplegic solution, antegrade cardioplegia is initiated for a period of time.

-51-

76. A method for manufacturing a self-filling balloon for use on a balloon catheter comprising the steps of:

obtaining a mandrel having a shape corresponding to the desired shape of the balloon and having a borehole therethrough which provides fluid communication from a borehole inlet to a borehole outlet located at the periphery of the mandrel;

dipping the mandrel into a polymer solution in order to coat the mandrel periphery with said polymer;

curing the polymer solution in order to form a balloon located about the mandrel periphery;

injecting a coating agent within the borehole entrance such that the coating agent exits the borehole through the borehole outlet and passes between the balloon and the mandrel periphery, thereby coating the inner surface of the balloon in contact with the mandrel, said coating agent functioning to lubricate the mandrel for easy removal of the balloon and to inhibit self adhesion of the balloon polymer; and

removing the balloon from the mandrel for subsequent attachment to the catheter.

77. A method for manufacturing a self-filling balloon as defined in claim 76, wherein the polymer comprises polyurethane.

78. A method for manufacturing a self-filling balloon as defined in claim 76, wherein the polymer solution comprises polyurethane having a concentration in the range from about 8% to about 9% in a solvent.

79. A method for manufacturing a self-filling balloon as defined in claim 78, wherein the solvent comprises

-52-

tetrahydrofuran.

80. A method for manufacturing a self-filling balloon as defined in claim 76, wherein the coating agent comprises silicone.

81. A method for manufacturing a self-filling balloon as defined in claim 80, wherein the coating agent comprises silicone dissolved in freon.

82. A method for manufacturing a self-filling balloon as defined in claim 81, wherein the concentration of silicone concentration in freon is in the range from about 3% to about 10%.

83. A method for manufacturing a self-filling balloon for use on a retrograde cardioplegia catheter, wherein cardioplegic solution flows through a lumen which fills the balloon with cardioplegic solution to sealingly engage the walls of the coronary sinus and which infuses the same cardioplegic solution within the coronary sinus, said method comprising the steps of:

obtaining a mandrel having a shape corresponding to the desired shape of the balloon and having a borehole therethrough which provides fluid communication from a borehole inlet to a borehole outlet located at the periphery of the mandrel;

dipping the mandrel into a polymer solution in order to coat the mandrel periphery with said polymer;

curing the polymer solution in order to form a balloon located about the mandrel periphery;

injecting a coating agent within the borehole entrance such that the coating agent exits the borehole through the borehole outlet and passes

SUBSTITUTE SHEET

-53-

between the balloon and the mandrel periphery, thereby coating the inner surface of the balloon in contact with the mandrel, said coating agent functioning to lubricate the mandrel for easy removal of the balloon and to inhibit self adhesion of the balloon polymer;

removing the balloon from the mandrel for subsequent attachment to the catheter;

obtaining a cannula;

cutting at least one balloon aperture in the cannula near the distal end of the cannula;

cutting at least one cannula outlet in the cannula distal of the at least one balloon aperture; and

attaching the balloon to the cannula such that the balloon forms a chamber between the balloon and the cannula and such that the cannula is in communication with the inner chamber through the at least one balloon aperture.

84. A method for manufacturing a retrograde cardioplegia catheter comprising the steps of:

obtaining a dual lumen cannula of a size capable of insertion into the coronary sinus of the heart, said cannula having an infusion lumen and a sensing lumen;

forming at least one balloon aperture in the infusion lumen near the distal end of the cannula having a total cross-sectional area which is greater than the cross-sectional area of the infusion lumen;

forming at least one infusion lumen outlet in the infusion lumen near the distal end of the cannula having a total cross-sectional area which is less than the cross-sectional area of the infusion lumen; and

-54-

attaching a balloon to the cannula such that the balloon and the cannula and such that the infusion lumen is in communication with the inner chamber through the balloon aperture, said balloon being manufactured by the steps of:

obtaining a mandrel having a shape corresponding to the desired shape of the balloon and having a borehole therethrough which provides fluid communication from a borehole entrance to a borehole outlet located at the periphery of the mandrel;

dipping the mandrel into a polymer solution in order to coat the mandrel periphery with said polymer;

curing the polymer solution in order to form a balloon located about the mandrel periphery;



injecting a coating agent within the borehole entrance such that the coating agent exits the borehole through the borehole outlet and passes between the balloon and the mandrel periphery thereby coating the inner surface of the balloon in contact with the mandrel, said coating agent functioning to lubricate the mandrel for easy removal of the balloon and to inhibit self adhesion of the balloon polymer; and

removing the balloon from the mandrel for subsequent attachment to the catheter.

SUBSTITUTE SHEET



1 / 4



SUBSTITUTE SHEET




FIG. 3




FIG. 4

**SUBSTITUTE SHEET**




FIG. 5

SUBSTITUTE SHEET




FIG. 6




FIG. 7




FIG. 8

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/01770

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (4): A61M, 25/00 U.S.Cl.: 604/96		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	604/51-53, 53-99, 102, 103, 264, 280 128/344	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	US,A, 4,210,478 (SHONEY), 01 JULY 1980. See Figures 4 and 5.	1-84
Y	US,A, 4,413,989 (SCHJELDAHL ET AL) 08 NOVEMBER 1983. See Abstract.	27-84
A	US,A, 4,459,977 (PIZON ET AL), 17 JULY 1984. See Abstract.	1-75
A	US,A, 4,610,661 (POSSIS ET AL), 09 SEPTEMBER 1986. See Abstract. Figure 5.	1-75
X Y	US,A, 4,689,041 (CORDAY ET AL), 25 AUGUST 1987. See entire document.	1,2,4-8,10,13,14,16 21
X Y	EP,A, 0,249,338 (SPECTOR ET AL), 06 DECEMBER 1987. See entire document.	1-84 1,2,4-8,10,13,16, 21
A	US,A 4,714,460 (CALDERON) 22 DECEMBER 1987. See Abstract.	1-84
A	The Journal of Thoracic and Cardiovascular Surgery, Vol. 59, no. 3, March 1970, Buckberg, "Retrograde Pulmonary Venous Pressure Measurement" pages 393-406.	1-75 1-84
A	Cardiopulmonary Perfusion, Texas Medical Press, Inc., Houston, Texas, 1975 Reed et al, "Chapter 19 - Cannulation" and "Chapter 23 - Myocardial Protection".	1-84
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
29 June 1989	17 JUL 1989	
International Searching Authority	Signature of Authorized Officer:	
ISA/US	Ralph Lewis <i>Ralph Lewis</i>	

**THIS PAGE BLANK (USPTO)**